Amgen Releases AMGEVITA for Treatment of Inflammatory Diseases in Adults
The AMGEVITA is a biosimilar designed to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis hidradenitis and panuveitis. The biosimilar is a citrate-free formula and will be released in twenty-eight countries in the European Union.This story is related to the following:Biopharmaceuticals
Source: Industrial Newsroom - Health, Medical and Dental Supplies - Category: Medical Devices Source Type: news
More News: Ankylosing Spondylitis | Arthritis | Hidradenitis | Medical Devices | Psoriasis | Psoriatic Arthritis | Rheumatoid Arthritis | Rheumatology